Novartis adds to its cache of Alnylam shares

Novartis has added to its cache of Alnylam stock, purchasing 55,223 shares at $17.99 each. The purchase maintains Novartis' 13.4 percent stake in the company. "This is now the third year that Novartis has elected to fully exercise their right to purchase additional shares under the Investor Rights Agreement, maintaining their current ownership percentage of Alnylam common stock," says CEO John Maraganore. "In addition, late last year Novartis elected to extend our collaboration for a fifth and final planned year, through October 2010." Novartis release

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.